Xilio Therapeutics Stock Price, News & Analysis

Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company focused on discovering and developing tumor-activated, or "masked," immuno-oncology (I-O) therapies for people living with cancer. According to the company’s public disclosures, its goal is to significantly improve outcomes for patients without the systemic side effects that can limit current I-O treatments. Xilio is advancing a pipeline of novel, tumor-activated molecules designed to localize anti-tumor activity within the tumor microenvironment and optimize the therapeutic index of potent immune-modulating agents.

Xilio states that it is leveraging a proprietary masking technology and tumor-activation platform to develop multiple classes of masked I-O therapies. These include tumor-activated cytokines, antibodies and immune cell engagers that are intended to remain largely inactive in healthy tissues and become activated in the tumor microenvironment. By harnessing protease activity and other features of the tumor microenvironment, the company aims to widen the therapeutic window for powerful immunotherapies that might otherwise cause dose-limiting toxicities when given systemically.

Core Pipeline and Programs

Based on the company’s recent press releases and SEC filings, Xilio’s pipeline includes several key investigational programs:

• Vilastobart: an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. Vilastobart is designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment. It is being evaluated in a multi-center, open-label Phase 1/2 clinical trial in combination with atezolizumab (Tecentriq) in patients with advanced solid tumors and in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), including those without liver metastases. Xilio has reported Phase 2 data in MSS mCRC, including objective responses in heavily pretreated patients without liver metastases and with high plasma tumor mutational burden, as well as data suggesting potential roles for plasma tumor mutational burden (TMB) and circulating tumor DNA (ctDNA) as biomarkers of response.
• Efarindodekin alfa (XTX301): an investigational tumor-activated interleukin-12 (IL-12) designed to stimulate anti-tumor immunity and reprogram poorly immunogenic "cold" tumors toward an inflamed or "hot" state. Efarindodekin alfa is being evaluated as a monotherapy in an ongoing first-in-human, multi-center, open-label Phase 1/2 clinical trial in patients with advanced solid tumors. Xilio has reported Phase 1 data showing monotherapy anti-tumor activity, including partial responses in heavily pretreated patients, and a safety profile that has allowed dosing at levels substantially higher than the maximum tolerated dose reported for recombinant human IL-12. The company has initiated patient dosing in the Phase 2 portion of this trial.
• XTX501: a novel, tumor-activated bispecific PD-1 / masked IL-2 molecule. Xilio describes XTX501 as designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function, with masking intended to overcome IL-2 receptor–mediated clearance and peripheral activity. In preclinical studies disclosed by the company, XTX501 demonstrated monotherapy activity, including in settings insensitive to PD-1, and tumor-selective pharmacodynamics consistent with its intended mechanism. XTX501 is advancing through investigational new drug (IND)-enabling studies with plans to submit an IND application.
• Masked T cell engager programs: Xilio is using its tumor-activation platform to develop multiple preclinical masked T cell engager programs. These include wholly owned programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1, and an additional program under a collaboration with AbbVie. The company has described two proprietary engager formats: the tumor-activated cell engager (ATACR) format, a bispecific T cell engager with a masked CD3 targeting domain, and the selective effector-enhanced cell engager (SEECR) format, a tri-specific design that adds co-stimulatory signaling. Preclinical data presented by Xilio indicate that these masked T cell engagers can demonstrate potent anti-tumor activity with evidence of reduced systemic toxicity in murine models and that incorporation of co-stimulation in the SEECR format can enhance durability of T cell activation.

Masking Technology and Tumor Microenvironment Focus

Across its programs, Xilio emphasizes a consistent design principle: tumor-activated masking intended to localize activity within the tumor microenvironment. For vilastobart, this approach is intended to enable CTLA-4 blockade and regulatory T cell depletion primarily in tumors, with the goal of reducing immune-related adverse events such as colitis that have historically limited systemic anti-CTLA-4 therapies. For efarindodekin alfa, the masked IL-12 design is intended to induce interferon gamma signaling, immune cell infiltration and upregulation of PD-1 and PD-L1 within tumors, while limiting systemic exposure associated with IL-12 toxicity.

For its masked T cell engager platform, Xilio reports that it leverages protease activity in the tumor microenvironment so that CD3-directed T cell engagement is preferentially activated in tumors. According to the company’s preclinical presentations, this design has shown potential to expand the therapeutic window relative to non-masked T cell engagers and to reduce systemic toxicity signals in animal models. The SEECR format adds co-stimulatory signaling to further enhance potency and durability of T cell responses in these models.

Strategic Collaborations and Partnerships

Xilio has entered into several collaborations with larger biopharmaceutical companies, as described in its news releases and SEC filings:

• Gilead Sciences: In March 2024, Xilio entered into an exclusive global license agreement with Gilead to develop and commercialize efarindodekin alfa and specified other molecules directed to IL-12. Xilio is responsible for clinical development of efarindodekin alfa through the initial Phase 2 portion of the ongoing Phase 1/2 trial. Following delivery of a specified clinical data package, Gilead may elect to assume development and commercialization responsibilities, subject to a transition fee and potential development, regulatory and sales-based milestone payments and royalties, as described in Xilio’s public disclosures.
• Roche: Xilio has a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab in a multi-center, open-label Phase 1/2 clinical trial in patients with advanced solid tumors and MSS metastatic colorectal cancer.
• AbbVie: Xilio has disclosed a collaboration, license and option agreement with AbbVie related to a masked antibody-based immunotherapy program and a masked T cell engager program. The company has reported achieving a development milestone under this agreement and is advancing a collaborative masked T cell engager program alongside its wholly owned PSMA, CLDN18.2 and STEAP1 programs.

Capital Markets and Listing Status

Xilio’s common stock trades under the symbol XLO. According to a Form 8-K filed on October 2, 2025, the company received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective October 6, 2025, while continuing to trade under the same ticker. In that filing, Xilio noted prior notifications from Nasdaq regarding the minimum bid price requirement and stockholders’ equity requirements for continued listing and disclosed that it had been granted an additional grace period to regain compliance with the minimum bid price requirement.

The company has also reported follow-on public offerings, warrant financings and warrant exercises, as well as the adoption of equity incentive plans and option repricings approved by stockholders, as part of its approach to funding operations and advancing its pipeline. In January 2026, Xilio disclosed that it had received gross proceeds from the exercise of Series B warrants and estimated a cash and cash equivalents balance as of the end of 2025, extending its projected cash runway based on its then-current operating plans.

Clinical and Scientific Focus Areas

The company’s disclosures highlight several scientific and clinical themes across its programs:

• Biomarker-driven development: For vilastobart in MSS mCRC, Xilio has reported data supporting the potential use of plasma-based tumor mutational burden as a predictive biomarker for response to treatment with vilastobart in combination with atezolizumab, and data suggesting that ctDNA reductions may serve as an early indicator of response.
• Cold-to-hot tumor conversion: For efarindodekin alfa, Xilio describes pharmacodynamic data showing sustained interferon gamma signaling, increased T cell infiltration and transformation of the tumor microenvironment toward an inflamed state, consistent with IL-12 biology.
• Masked T cell engagement: For its masked T cell engager programs, the company emphasizes preclinical evidence that masking and tumor-selective activation can provide potent anti-tumor activity with reduced systemic toxicity in animal models, and that co-stimulatory signaling in the SEECR format can enhance the durability of anti-tumor responses.

Corporate Governance and Stockholder Matters

Xilio is incorporated in Delaware and files periodic reports, proxy statements and current reports with the U.S. Securities and Exchange Commission. In 2025, the company filed a definitive proxy statement for a special meeting of stockholders to consider, among other items, approval of a one-time repricing of certain outstanding employee stock options and approval of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan. Subsequent Form 8-K filings report that stockholders approved these proposals and that the option repricing was implemented.

The company has also disclosed changes in board leadership, including the appointment of a new chair of the board of directors following the retirement of the prior chair. These governance updates are described in its press releases and related Form 8-K filings.

Position Within Biotechnology and Immuno-Oncology

Within the broader biotechnology and immuno-oncology landscape, Xilio characterizes itself as a company focused on tumor-activated, or masked, therapies designed to address limitations of existing systemic immunotherapies. Its programs span checkpoint modulation (anti-CTLA-4), cytokine therapy (IL-12), bispecific PD-1/IL-2 molecules and masked T cell engagers targeting defined tumor-associated antigens. The company’s public communications emphasize the potential for its masking technology and tumor-activation platform to be applied across multiple modalities and targets.

Investors and observers can follow Xilio’s progress through its clinical trial disclosures, scientific presentations at meetings such as the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), press releases on pipeline and business updates, and SEC filings that provide additional detail on collaborations, financings and corporate actions.